Disc Medicine Inc [IRON] stock prices are down -1.48% to $87.0 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IRON shares have gain 1.46% over the last week, with a monthly amount glided 23.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $86. TD Cowen initiated its recommendation with a Buy. Morgan Stanley upgraded its rating to Overweight for this stock on November 05, 2024, but kept the price target unchanged to $85. In a note dated November 04, 2024, Raymond James upgraded an Strong Buy rating on this stock and boosted its target price from $66 to $110.
The stock price of Disc Medicine Inc [IRON] has been fluctuating between $30.82 and $95.95 over the past year. Currently, Wall Street analysts expect the stock to reach $123.67 within the next 12 months. Disc Medicine Inc [NASDAQ: IRON] shares were valued at $87.0 at the most recent close of the market. An investor can expect a potential return of 42.15% based on the average IRON price forecast.
Analyzing the IRON fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.27 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 85.34 points at the first support level, and at 83.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 89.52, and for the 2nd resistance point, it is at 92.05.
Ratios To Look Out For
It’s worth pointing out that Disc Medicine Inc [NASDAQ:IRON]’s Current Ratio is 32.11. In addition, the Quick Ratio stands at 32.11 and the Cash Ratio stands at 6.18.
Transactions by insiders
Recent insider trading involved AI DMI LLC, 10% Owner, that happened on Oct 22 ’25 when 0.74 million shares were sold. Shareholder, OrbiMed Private Investments VI completed a deal on Oct 20 ’25 to buy 0.48 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 0.19 million shares on Oct 20 ’25.
